Which of the following is a non-steroidal antiandrogen that is palliative in advanced carcinoma prostate when combined with a GnRH agonist: A. Cyproterone acetate B. Danazol C. Finasteride D. Flutamid

Which of the following is a non-steroidal antiandrogen that is palliative in advanced carcinoma prostate when combined with a GnRH agonist:
A. Cyproterone acetate
B. Danazol
C. Finasteride
D. Flutamid
by

1 Answer

Answer :

D. Flutamide
by

Related questions

Circulating testosterone levels in men are elevated during treatment with: A. Danazol B. Finasteride C. Flutamide D. Ketoconazole

Description : Circulating testosterone levels in men are elevated during treatment with: A. Danazol B. Finasteride C. Flutamide D. Ketoconazole

Last Answer : C. Flutamide

Tamoxifen citrate is used for palliative treatment of carcinoma breast in: A. Premenopausal women B. Postmenopausal women C. Mastectomized patients D. All of the above

Description : Tamoxifen citrate is used for palliative treatment of carcinoma breast in: A. Premenopausal women B. Postmenopausal women C. Mastectomized patients D. All of the above

Last Answer : D. All of the above

Estrogens are palliative in the following malignancy: A. Carcinoma breast B. Carcinoma cervix C. Endometrial carcinoma D. Carcinoma prostate

Description : Estrogens are palliative in the following malignancy: A. Carcinoma breast B. Carcinoma cervix C. Endometrial carcinoma D. Carcinoma prostate

Last Answer : D. Carcinoma prostate

Select the correct statement about tibolone: A. It is an antiestrogen used for palliative treatment of carcinoma breast B. It is an estrogenic + progestational steroid used for hormone replacement therapy in postmenopausal women C. It is an antiandrogen used for male pattern baldness D. It is a nonsteroidal estrogen used topically for senile vaginitis

Description : Select the correct statement about tibolone: A. It is an antiestrogen used for palliative treatment of carcinoma breast B. It is an estrogenic + progestational steroid used for hormone replacement ... for male pattern baldness D. It is a nonsteroidal estrogen used topically for senile vaginitis

Last Answer : B. It is an estrogenic + progestational steroid used for hormone replacement therapy in postmenopausal women

The following has been found to act as a male contraceptive without affecting libido or potency: A. Cyproterone acetate B. Goserelin C. Centchroman D. Gossypol

Description : The following has been found to act as a male contraceptive without affecting libido or potency: A. Cyproterone acetate B. Goserelin C. Centchroman D. Gossypol

Last Answer : D. Gossypol

The following drug has potent antiandrogenic and weak progestational activity: A. Ethylestrenol B. Clomiphene citrate C. Cyproterone acetate D. Magestrol acetate

Description : The following drug has potent antiandrogenic and weak progestational activity: A. Ethylestrenol B. Clomiphene citrate C. Cyproterone acetate D. Magestrol acetate

Last Answer : D. Magestrol acetate

Which of the following can act as a single dose postcoital contraceptive: A. Clomiphene citrate B. Mifepristone C. Danazol D. Medroxyprogesterone acetate

Description : Which of the following can act as a single dose postcoital contraceptive: A. Clomiphene citrate B. Mifepristone C. Danazol D. Medroxyprogesterone acetate

Last Answer : B. Mifepristone

Health benefits afforded by the combined estrogenprogestin oral contraceptive pill include the following except: A. Reduced menstrual blood loss B. Lower risk of fibrocystic breast disease C. Lower risk of myocardial infarction D. Lower risk of endometrial carcinoma

Description : Health benefits afforded by the combined estrogenprogestin oral contraceptive pill include the following except: A. Reduced menstrual blood loss B. Lower risk of fibrocystic breast disease C. Lower risk of myocardial infarction D. Lower risk of endometrial carcinoma

Last Answer : . Lower risk of myocardial infarction

The purpose/purposes served by the progestin component of the combined estrogen + progestin contraceptive pill is/are: A. Suppression of ovulation B. Prompt bleeding at the end of the course C. Blockade of increased risk of endometrial carcinoma D. All of the above

Description : The purpose/purposes served by the progestin component of the combined estrogen + progestin contraceptive pill is/are: A. Suppression of ovulation B. Prompt bleeding at the end of the course C. Blockade of increased risk of endometrial carcinoma D. All of the above

Last Answer : D. All of the above

The following does not apply to cancer chemotherapy: A. Each treatment with a cytotoxic drug kills a constant number of malignant cells B. Drugs are generally used at maximum tolerated doses C. The same regimen which is palliative for a large solid tumour may be curative after surgical removal of the tumour D. Combination regimens using several drugs in succession are superior to single drug used continuously

Description : The following does not apply to cancer chemotherapy: A. Each treatment with a cytotoxic drug kills a constant number of malignant cells B. Drugs are generally used at maximum tolerated ... D. Combination regimens using several drugs in succession are superior to single drug used continuously

Last Answer : A. Each treatment with a cytotoxic drug kills a constant number of malignant cells

The following is true of selegiline: A. It does not exert antiparkinsonian action unless combined with levodopa B. It overcomes the ‘on-off ’ effect in levodopa treated advanced parkinsonian patients C. It retards the progression of Parkinson's disease D. At doses used in parkinsonism it does not interfere with peripheral metabolism of dietary amines

Description : The following is true of selegiline: A. It does not exert antiparkinsonian action unless combined with levodopa B. It overcomes the on-off ' effect in levodopa treated advanced parkinsonian ... D. At doses used in parkinsonism it does not interfere with peripheral metabolism of dietary amines

Last Answer : . At doses used in parkinsonism it does not interfere with peripheral metabolism of dietary amines

The following is/are beneficial in endometriosis: A. Norethindrone B. Nafarelin C. Danazol D. All of the above

Description : The following is/are beneficial in endometriosis: A. Norethindrone B. Nafarelin C. Danazol D. All of the above

Last Answer : D. All of the above

Choose the selective estrogen receptor modulator that is useful in dysfunctional uterine bleeding by acting as estrogen antagonist in endometrium, but does not alter vaginal epithelium or cervical mucus: A. Ormeloxifene B. Tamoxifen C. Centchroman D. Danazol

Description : Choose the selective estrogen receptor modulator that is useful in dysfunctional uterine bleeding by acting as estrogen antagonist in endometrium, but does not alter vaginal epithelium or cervical mucus: A. Ormeloxifene B. Tamoxifen C. Centchroman D. Danazol

Last Answer : . Ormeloxifen

The following is an orally active ovulation inducing agent: A. Menotropin B. Mifepristone C. Danazol D. Clomiphene citrate

Description : The following is an orally active ovulation inducing agent: A. Menotropin B. Mifepristone C. Danazol D. Clomiphene citrate

Last Answer : D. Clomiphene citrate

Danazol produces the following side effects in premenopausal women except: A. Acne B. Menorrhagia C. Amenorrhoea D. Hot flashes

Description : Danazol produces the following side effects in premenopausal women except: A. Acne B. Menorrhagia C. Amenorrhoea D. Hot flashes

Last Answer : B. Menorrhagia

Danazol is used for the following disorders except: A. Amenorrhoea B. Endometriosis C. Fibrocystic breast disease D. Precocious puberty in male children

Description : Danazol is used for the following disorders except: A. Amenorrhoea B. Endometriosis C. Fibrocystic breast disease D. Precocious puberty in male children

Last Answer : A. Amenorrhoea

Finasteride acts by: A. Blocking testosterone receptors in the prostate gland B. Reducing testosterone secretion from testes C. Reducing LH secretion from pituitary D. Lowering circulating as well as prostatic dihydrotestosterone concentration

Description : Finasteride acts by: A. Blocking testosterone receptors in the prostate gland B. Reducing testosterone secretion from testes C. Reducing LH secretion from pituitary D. Lowering circulating as well as prostatic dihydrotestosterone concentration

Last Answer : D. Lowering circulating as well as prostatic dihydrotestosterone concentration

Which of the following is a steroid 5α-reductase inhibitor that has been found useful in benign prostatic hypertrophy and male pattern baldness: A. Flutamide B. Finasteride C. Prazosin D. Minoxidil

Description : Which of the following is a steroid 5α-reductase inhibitor that has been found useful in benign prostatic hypertrophy and male pattern baldness: A. Flutamide B. Finasteride C. Prazosin D. Minoxidil

Last Answer : B. Finasteride

Select the drug that primarily reduces the static component of urinary obstruction in benign hypertrophy of prostate and takes more than 3 months to exert its beneficial effect: A. Tamsulosin B. Terazosin C. Finasteride D. Amphetamine

Description : Select the drug that primarily reduces the static component of urinary obstruction in benign hypertrophy of prostate and takes more than 3 months to exert its beneficial effect: A. Tamsulosin B. Terazosin C. Finasteride D. Amphetamine

Last Answer : C. Finasteride

Select the drug which can improve urinary flow rate in benign prostatic hypertrophy without affecting prostate size: A. Amphetamine B. Prazosin C. Finasteride D. Goserelin

Description : Select the drug which can improve urinary flow rate in benign prostatic hypertrophy without affecting prostate size: A. Amphetamine B. Prazosin C. Finasteride D. Goserelin

Last Answer : B. Prazosin

Select the drug which affords faster and greater symptomatic relief in benign hypertrophy of prostate: A. Terazosin B. Desmopressin C. Finasteride D. Sildenafi

Description : Select the drug which affords faster and greater symptomatic relief in benign hypertrophy of prostate: A. Terazosin B. Desmopressin C. Finasteride D. Sildenafi

Last Answer : A. Terazosin

Select the drug which can improve urinary flow rate in benign prostatic hypertrophy without affecting prostate size: A. Amphetamine B. Prazosin C. Finasteride D. Goserelin

Description : Select the drug which can improve urinary flow rate in benign prostatic hypertrophy without affecting prostate size: A. Amphetamine B. Prazosin C. Finasteride D. Goserelin

Last Answer : B. Prazosin

Select the drug which affords faster and greater symptomatic relief in benign hypertrophy of prostate: A. Terazosin B. Desmopressin C. Finasteride D. Sildenafil

Description : Select the drug which affords faster and greater symptomatic relief in benign hypertrophy of prostate: A. Terazosin B. Desmopressin C. Finasteride D. Sildenafil

Last Answer : A. Terazosin

Superactive GnRH agonists cause: A. Initial as well as sustained release of gonadotropins B. Initial inhibition followed by stimulation of gonadotropin release after 1-2 weeks C. Initial stimulation followed by inhibition of gonadotropin release after 1-2 weeks D. Initial as well as sustained inhibition of gonadotropin release

Description : Superactive GnRH agonists cause: A. Initial as well as sustained release of gonadotropins B. Initial inhibition followed by stimulation of gonadotropin release after 1-2 weeks C. Initial stimulation ... release after 1-2 weeks D. Initial as well as sustained inhibition of gonadotropin release

Last Answer : C. Initial stimulation followed by inhibition of gonadotropin release after 1-2 weeks

16.17 Superactive GnRH agonists cause: A. Initial as well as sustained release of gonadotropins B. Initial inhibition followed by stimulation of gonadotropin release after 1-2 weeks C. Initial stimulation followed by inhibition of gonadotropin release after 1-2 weeks D. Initial as well as sustained inhibition of gonadotropin release

Description : 16.17 Superactive GnRH agonists cause: A. Initial as well as sustained release of gonadotropins B. Initial inhibition followed by stimulation of gonadotropin release after 1-2 weeks C. Initial ... release after 1-2 weeks D. Initial as well as sustained inhibition of gonadotropin release

Last Answer : C. Initial stimulation followed by inhibition of gonadotropin release after 1-2 weeks

16.15 The hypothalamic gonadotropin releasing hormone (GnRH) is: A. A single peptide B. A mixture of two distinct peptides FSH-RH and LH-RH C. A mixture of several peptides D. Dopamine

Description : 16.15 The hypothalamic gonadotropin releasing hormone (GnRH) is: A. A single peptide B. A mixture of two distinct peptides FSH-RH and LH-RH C. A mixture of several peptides D. Dopamine

Last Answer : A. A single peptide

he following anthelmintic acts as a cholinergic agonist in the nematodes and causes spastic paralysis of the worms: A. Piperazine B. Pyrantel pamoate C. Mebendazole D. Thiabendazole

Description : he following anthelmintic acts as a cholinergic agonist in the nematodes and causes spastic paralysis of the worms: A. Piperazine B. Pyrantel pamoate C. Mebendazole D. Thiabendazole

Last Answer : B. Pyrantel pamoate

he following is true of desmopressin except: A. It is nonselective V1 and V2 receptor agonist B. It is more potent and longer acting than arginine vasopressin (AVP) C. It is preferred over AVP for treatment of diabetes insipidus D. It can be administered orally

Description : Che following is true of desmopressin except: A. It is nonselective V1 and V2 receptor agonist B. It is more potent and longer acting than arginine vasopressin (AVP) C. It is preferred over AVP for treatment of diabetes insipidus D. It can be administered orally

Last Answer : A. It is nonselective V1 and V2 receptor agonist

Which of the following peptides is a selective vasopressin V2 receptor agonist: A. Arginine vasopressin B. Desmopressin C. Lypessin D. Terlipressin

Description : Which of the following peptides is a selective vasopressin V2 receptor agonist: A. Arginine vasopressin B. Desmopressin C. Lypessin D. Terlipressin

Last Answer : B. Desmopressin

Losartan is a: A. Selective AT1 receptor antagonist B. Selective AT2 receptor antagonist C. Nonselective AT1 + AT2 receptor antagonist D. AT1 receptor partial agonist

Description : Losartan is a: A. Selective AT1 receptor antagonist B. Selective AT2 receptor antagonist C. Nonselective AT1 + AT2 receptor antagonist D. AT1 receptor partial agonist

Last Answer : A. Selective AT1 receptor antagonist

The following is true of buprenorphine: A. It is an agonist-antagonist type of opioid analgesic B. Its subjective effects are different from those of morphine C. Naloxone is largely ineffective in reversing its effects D. It produces mydriasis

Description : The following is true of buprenorphine: A. It is an agonist-antagonist type of opioid analgesic B. Its subjective effects are different from those of morphine C. Naloxone is largely ineffective in reversing its effects D. It produces mydriasis

Last Answer : C. Naloxone is largely ineffective in reversing its effects

Which of the following is an agonist-antagonist type of opioid analgesic: A. Pethidine B. Pentazocine C. Fentanyl D. Buprenorphine

Description : Which of the following is an agonist-antagonist type of opioid analgesic: A. Pethidine B. Pentazocine C. Fentanyl D. Buprenorphine

Last Answer : B. Pentazocine

The following statement is correct about buspirone: A. It interacts with benzodiazepine receptor as an inverse agonist B. It is a rapidly acting anxiolytic, good for panic states C. It produces physical dependence and suppresses barbiturate withdrawal syndrome D. It has anxiolytic but no anticonvulsant or muscle relaxant propert

Description : The following statement is correct about buspirone: A. It interacts with benzodiazepine receptor as an inverse agonist B. It is a rapidly acting anxiolytic, good for panic states C. ... suppresses barbiturate withdrawal syndrome D. It has anxiolytic but no anticonvulsant or muscle relaxant propert

Last Answer : D. It has anxiolytic but no anticonvulsant or muscle relaxant property

The following category of drugs is not indicated in early/mild cases of Parkinson's disease: A. Central anticholinergic B. MAO-B inhibitor C. COMT inhibitor D. Nonergoline dopaminergic agonist

Description : The following category of drugs is not indicated in early/mild cases of Parkinson's disease: A. Central anticholinergic B. MAO-B inhibitor C. COMT inhibitor D. Nonergoline dopaminergic agonist

Last Answer : C. COMT inhibitor

Gabapentin acts: A. As GABAA agonist B. As precursor of GABA C. By enhancing GABA release D. By GABA independent mechanism

Description : Gabapentin acts: A. As GABAA agonist B. As precursor of GABA C. By enhancing GABA release D. By GABA independent mechanism

Last Answer : C. By enhancing GABA release

Choose the correct statement about lamotrigine: A. It is a dopaminergic agonist used in parkinsonism B. It acts by blocking NMDA-type of glutamate receptors C. It is a broad spectrum antiepileptic drug D. It suppresses tonic-clonic seizures, but worsens absence seizures

Description : Choose the correct statement about lamotrigine: A. It is a dopaminergic agonist used in parkinsonism B. It acts by blocking NMDA-type of glutamate receptors C. It is a broad spectrum antiepileptic drug D. It suppresses tonic-clonic seizures, but worsens absence seizures

Last Answer : C. It is a broad spectrum antiepileptic drug

The following is a skeletal muscle relaxant that acts as a central α2 adrenergic agonist: A. Tizanidine B. Brimonidine C. Chlormezanone D. Quinine

Description : The following is a skeletal muscle relaxant that acts as a central α2 adrenergic agonist: A. Tizanidine B. Brimonidine C. Chlormezanone D. Quinine

Last Answer : A. Tizanidine

The following is true of raloxifene except: A. It acts as an estrogen agonist in bone B. It exerts estrogen antagonistic action on endometrium C. It increases risk of developing breast cancer D. It can induce/aggravate menopausal hot flushes

Description : The following is true of raloxifene except: A. It acts as an estrogen agonist in bone B. It exerts estrogen antagonistic action on endometrium C. It increases risk of developing breast cancer D. It can induce/aggravate menopausal hot flushes

Last Answer : C. It has additional androgenic acitivity

Choose the correct statement(s) about pioglitazone: A. It acts as an agonist on nuclear paroxisome proliferator receptor γ B. It enhances transcription of insulin responsive genes C. It lowers blood sugar in type 2 diabetes mellitus without causing hyperinsulinemia D. All of the above

Description : Choose the correct statement(s) about pioglitazone: A. It acts as an agonist on nuclear paroxisome proliferator receptor γ B. It enhances transcription of insulin responsive genes C. It lowers blood sugar in type 2 diabetes mellitus without causing hyperinsulinemia D. All of the above

Last Answer : D. All of the above

The following is an α2 adrenergic agonist used as eyedrops to lower intraocular pressure: A. Brinzolamide B. Bambuterol C. Brimonidine D. Latanoprost

Description : The following is an α2 adrenergic agonist used as eyedrops to lower intraocular pressure: A. Brinzolamide B. Bambuterol C. Brimonidine D. Latanoprost

Last Answer : C. Brimonidine

Agonist induced autophosphorylation, internalization and down regulation is a distinctive feature of: A. G-protein coupled receptors B. Intrinsic ion channel containing receptors C. Tyrosine protein kinase receptors D. Receptors regulating gene expression

Description : Agonist induced autophosphorylation, internalization and down regulation is a distinctive feature of: A. G-protein coupled receptors B. Intrinsic ion channel containing receptors C. Tyrosine protein kinase receptors D. Receptors regulating gene expression

Last Answer : C. Tyrosine protein kinase receptors

The following is a selective 5-HT4 agonist: A. Buspirone B. Sumatriptan C. Cisapride D. Clozapine

Description : The following is a selective 5-HT4 agonist: A. Buspirone B. Sumatriptan C. Cisapride D. Clozapine

Last Answer : C. Cisapride

The following is an α 2 adrenergic agonist used as eyedrops to lower intraocular pressure: A. Brinzolamide B. Bambuterol C. Brimonidine D. Latanoprost

Description : The following is an α 2 adrenergic agonist used as eyedrops to lower intraocular pressure: A. Brinzolamide B. Bambuterol C. Brimonidine D. Latanoprost

Last Answer : C. Brimonidine

ndicate the anti-HIV regimen that is generally reserved for advanced cases of AIDS or for repeated treatment failures: A. Two nucleoside reverse transcriptase inhibitors (NRTIs) + one protease inhibitor (PI) B. Three NRTIs C. Two NRTIs + one non-NRTI D. One NRTI + one non-NRTI + one PI

Description : ndicate the anti-HIV regimen that is generally reserved for advanced cases of AIDS or for repeated treatment failures: A. Two nucleoside reverse transcriptase inhibitors (NRTIs) + one protease inhibitor (PI) B. Three NRTIs C. Two NRTIs + one non-NRTI D. One NRTI + one non-NRTI + one PI

Last Answer : D. One NRTI + one non-NRTI + one PI

Which of the following neoplastic diseases is almost curable by chemotherapy: A. Bronchogenic carcinoma B. Choriocarcinoma C. Malignant melanoma D. Colorectal carcinoma

Description : Which of the following neoplastic diseases is almost curable by chemotherapy: A. Bronchogenic carcinoma B. Choriocarcinoma C. Malignant melanoma D. Colorectal carcinoma

Last Answer : B. Choriocarcinoma

Oral contraceptive use increases the risk of occurrence of the following diseases except: A. Hypertension B. Leg vein thrombosis C. Endometrial carcinoma D. Gall stones

Description : Oral contraceptive use increases the risk of occurrence of the following diseases except: A. Hypertension B. Leg vein thrombosis C. Endometrial carcinoma D. Gall stones

Last Answer : C. Endometrial carcinoma

The primary indication of tamoxiphen citrate is: A. Female infertility B. Endometrial carcinoma C. Carcinoma breast D. Endometriosis

Description : The primary indication of tamoxiphen citrate is: A. Female infertility B. Endometrial carcinoma C. Carcinoma breast D. Endometriosis

Last Answer : C. Carcinoma breast

Addition of a progestin for 10-12 days each month to estrogen replacement therapy in menopausal women is recommended because the progestin: A. Blocks the increased risk of myocardial infarction due to estrogen B. Blocks the increased risk of endometrial carcinoma due to estrogen C. Reverses vulval atrophy occurring in postmenopausal women D. Enhances the metabolic benefits of estrogen treatment

Description : Addition of a progestin for 10-12 days each month to estrogen replacement therapy in menopausal women is recommended because the progestin: A. Blocks the increased risk of myocardial ... vulval atrophy occurring in postmenopausal women D. Enhances the metabolic benefits of estrogen treatment

Last Answer : The estrogen commonly used for hormone replacement therapy in menopausal women is: A. Ethinylestradiol B. Estradiol benzoate C. Diethylstilbestrol D. Conjugated estrogens

Estrogen therapy in postmenopausal women has been implicated in increasing the risk of the following disorders except: A. Gall stones B. Osteoporosis C. Endometrial carcinoma D. Breast cancer

Description : Estrogen therapy in postmenopausal women has been implicated in increasing the risk of the following disorders except: A. Gall stones B. Osteoporosis C. Endometrial carcinoma D. Breast cancer

Last Answer : B. Osteoporosis